The U.S. Supreme Court recently issued its decision in Amgen Inc. v. Sanofi; a decision long-awaited by patent practitioners. In its decision, the Court unanimously held that several of Amgen’s patent claims to a class of antibodies were invalid for lack of enablement.
Under U.S. law, patent marking is optional. One may ask, well, then why do it? The short answer; damages.
If your client’s invention is focused on, or relates to, achieving net-zero greenhouse gas emissions, the U.S. Patent and Trademark Office (USPTO) is in your corner, now more than ever. On June 6, 2023, the USPTO expanded the eligibility requirements of the Climate Change Mitigation Pilot Program to apply to a greater breadth of technologies.
In April 2023, the U.S. Patent & Trademark Office (USPTO) announced proposed changes to some of the fees that it charges with respect to patent applications, design patents and America Invents Act trials.
- EventHealth Law Webinar: Avoiding the Medicare (and Medicaid) Death Penalty: How Seemingly Minor Errors Can Get Organizations Deactivated, Terminated or Barred
- EventOpportunity to Lead: Leadership Lessons From the 2026 Special Olympics USA Games
- EventPFAS Regulations Are Evolving: What Midwest Businesses Need to Know Now – Day 2
- EventLet’s Talk About Tax – An Annual Sampler 2026